Trial intelligence / Profile preview

2 versus 3 cycles of docetaxel + cisplatin induction chemotherapy before concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma

ChiCTR-IIR-17012529Phase 3Recruiting

Sponsor
Xiangya Hospital, Central South University
Start
Sep 2017
Modality
Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial of docetaxel and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoint: Progression-free survival. Started Sep 2017; status: recruiting.

02

Drugs

docetaxelcisplatin
03

Conditions

nasopharyngeal carcinoma (NPC)

Beyond the preview

Go deeper on ChiCTR-IIR-17012529.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR-IIR-17012529.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call